Cardiology
Mehran Score for Post-PCI Contrast Nephropathy
Predicts risk of contrast-induced nephropathy (CIN) following percutaneous coronary intervention (PCI).
References
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- DAPT Score · Coronary Artery Disease
- Canadian Cardiovascular Society (CCS) Angina Grading · Coronary Artery Disease
- Duke Treadmill Score · Coronary Artery Disease
- ARC-HBR Criteria for High Bleeding Risk in PCI · Coronary Artery Disease
- PRECISE-DAPT Score for Bleeding on DAPT · Coronary Artery Disease
- SYNTAX Score for Coronary Artery Disease · Coronary Artery Disease
Drugs
- Colchicine (Pericarditis / Post-MI Inflammation) · Pericarditis / Coronary Inflammation
- N-Acetylcysteine (Contrast Nephropathy) · Contrast-Induced Nephropathy Prevention
- Lisinopril (HFrEF / Post-MI) · ACE Inhibitor / HFrEF
- Clopidogrel (ACS / Post-PCI) · Antiplatelet / ACS
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Acetazolamide (Ménière's Disease) · Carbonic Anhydrase Inhibitor (Diuretic)
Pathways
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.